Dupilumab Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis

Exclusion criteria

• ✕. Biologic therapy/systemic immunosuppressant to treat inflammatory disease or autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, etc) within 2 months before screening or 5 half-lives, whichever is longer
• ✕. An experimental monoclonal antibody within five half-lives or within 6 months before screening if the half-life is unknown
• ✕. Anti-immunoglobulin E (IgE) therapy (omalizumab) within 130 days prior to screening
• ✕. Leukotriene antagonists/modifiers unless patient is on a continuous treatment for at least 30 days prior to screening
• ✕. Initiation of allergen immunotherapy within 3 months prior to screening or a plan to begin therapy or change its dose during the run-in period or the randomized treatment period
• ✕. Antrochoanal polyps
• ✕. Nasal septal deviation that would occlude at least one nostril
• ✕. Acute sinusitis, nasal infection or upper respiratory infection at screening